Background: Biologics targeting interleukin 17A (IL-17A) allow for rapid clearance of psoriatic plaques, with a clinically favorable safety profile.
Results: At week 52, significantly more ixekizumab-treated patients (P \ Limitations: This study was not designed to compare safety end points related to rare events. Key words: biologic; clinical trial; efficacy; ixekizumab; IXORA-S; psoriasis; safety; ustekinumab.
Conclusions
Recent advances in understanding of the pathophysiology of psoriasis have highlighted a key role for the interleukin 23 (IL-23)/ IL-17 pathway. [1] [2] [3] [4] [5] [6] New treatments targeting these cytokines have allowed for high levels of clearance, with a favorable safety profile. [7] [8] [9] [10] [11] [12] [13] Ixekizumab is a highaffinity, monoclonal IL-17A antagonist 14 that has demonstrated efficacy at both shortand long-term time points in 3 phase 3 clinical trials, with a favorable safety profile. 7, 8, 15 IXORA-S is the first head-to-head trial providing 52-week comparative data between ixekizumab and another biologic targeting the IL-23/IL-17 pathway. 16 As psoriasis is a lifelong disease, longterm comparison of therapeutic agents is important and clinically relevant.
Efficacy and high-level safety data up to week 24 from IXORA-S have been previously reported. 16 Herein, we present the safety and efficacy of ixekizumab compared with ustekinumab from a 1-year, double-blind, randomized, controlled trial.
METHODS

Study design and treatments
In this 52-week, phase 3b, double-blind, head-tohead trial (IXORA-S [NCT02561806]), eligible patients 16 with moderate-to-severe plaque psoriasis were randomized 1:1 to receive subcutaneous injections of either ixekizumab or ustekinumab per the recommended dosing regimen (Fig 1) . 17, 18 Matching placebo injections were used to maintain blinding. The study methods were previously described in depth. 16 
Study population
Eligibility and exclusion criteria have been reported previously. 16 Of note, eligible study participants had to have previously failed or had a contraindication to or intolerance of at least 1 systemic therapy; in addition, they had to have had a baseline Psoriasis Area and Severity Index (PASI) score of 10 or higher and could not have had prior treatment with ustekinumab, ixekizumab, or any other IL-17 or IL-12/23 antagonists.
The study was approved by the applicable ethical review boards, and all patients signed informed consent forms before undergoing study-related procedures. The study was conducted in compliance with the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines. The first patient randomization occurred on October 21, 2015, and the week 52 last patient visit was on May 15, 2017.
Efficacy assessments
The primary objective of IXORA-S was to demonstrate superiority of ixekizumab over ustekinumab at week 12, as assessed by the proportion of patients achieving a 90% or greater improvement from baseline PASI score (PASI 90). 16 Here, results of the primary end point and key secondary end points are presented through week 52, which was the final assessment time point. These end points include the proportion of patients achieving a 75% or greater improvement from baseline PASI score (PASI 75), PASI 90, or a 100% improvement from baseline PASI score (PASI 100) and a static Physician's Global
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The superior efficacy of ixekizumab over ustekinumab observed at earlier time points is maintained through week 52. Over 52 weeks, the overall safety of ixekizumab was comparable to that of ustekinumab.
Assessment (sPGA) response of 0 or 1 or an sPGA response of 0.
Safety assessments
Safety was assessed on the basis of patientreported adverse events (AEs), laboratory values, and vital signs obtained at study visits. Treatmentemergent AEs (TEAEs) were defined as those that first occurred or worsened after baseline (ie, first injection) and on or before the date of last visit. AEs of special interest included cytopenias, changes in liver function test results or elevations of enzyme levels, infections, injection site reactions, malignancies, depression, allergic or hypersensitivity reactions, cerebrovascular and cardiovascular events, inflammatory bowel disease, and Pneumocystis pneumonia and interstitial lung disease. Medical Dictionary for Regulatory Activities preferred terms associated with major cerebrovascular and cardiovascular events were independently adjudicated by an external committee.
Statistical analyses
Patients were analyzed according to their assigned treatment at randomization (intent-to-treat population). Binary end points at week 52 were assessed via logistic regression with nonresponder imputation (NRI). Logistic regression models included terms for treatment group, weight, and geographic region (Eastern Europe, Western Europe, or North America). Analysis of covariance models included terms for baseline value, treatment group, weight, and geographic region. Subgroup analyses were performed by including a term for subgroup and its subgroup-by-treatment interaction in the logistic regression or analysis of covariance model. Comparisons of secondary outcomes over time were made by using Fisher's exact test. Unless otherwise noted, all analyses were prespecified. Post hoc, the number of patients needed to treat (NNT) for 1 additional patient to benefit of PASI 75, PASI 90, or PASI 100 was estimated by using the published methodology. 19 Safety analyses were performed in patients who received at least 1 dose of study treatment (the safety population) and according to the treatment received. Safety events were analyzed by using Fisher's exact test. Study design for IXORA-S. Patients were randomized 1:1 to receive either ixekizumab or ustekinumab. Arrows indicate active injections. Ixekizumab-treated patients received a subcutaneous (SC) 160-mg starting dose (2 SC injections of 80 mg) at week 0. This was followed by 80-mg SC injections given every 2 weeks until week 12 and every 4 weeks thereafter. The dose of ustekinumab administered to patients in the ustekinumab group was per the label and based on weight. Patients weighing 100.0 kg or less received 45-mg SC injections and patients weighing more than 100.0 kg received 90-mg SC injections. The primary end point of the study was the proportion of patients achieving a 90% or greater improvement in Psoriasis Area Severity Index from baseline at week 12 (PASI 90); an interim database analysis was done and published for week 24. 16 The last active injections were given at week 48 for the ixekizumab-treated patients and at week 40 for the ustekinumab-treated patients; the last patient visit was at week 52 for both treatment groups. P values were considered statistically significant at the 2-sided 5% a level, and confidence intervals (CIs) were at the 95% level. All analyses were conducted with SAS software (version 9.4, SAS Institute Inc, Cary, NC).
RESULTS
Study population
Of the 355 patients screened for IXORA-S (Fig 2) , 302 were randomized to receive ustekinumab (n = 166) or ixekizumab (n = 136). The numbers of patients in both treatment groups who discontinued during the maintenance period were comparable, with 91% of patients completing the study through Baseline characteristics were balanced between treatment groups (Table I) . 16 
Clinical efficacy
For all clinical efficacy measurements, the superiority of ixekizumab that was demonstrated at weeks 12 and 24 16 persisted at all time points through week 52 (Table II and Fig 3) . Of the ustekinumab-treated patients, 59.0% (n = 98) and 35.5% (n = 59) showed PASI 90 and PASI 100 responses, respectively, at week 52, whereas 76.5% of patients in the ixekizumab treatment group (n = 104) maintained PASI 90 and 52.2% (n = 71) had completely clear skin (PASI 100). The rates of an sPGA response of 0 or 1 and an sPGA response of 0 at week 52 were 65.1% and 36.1% (n = 108 and 60), respectively, for ustekinumab and 82.1% and 52.9% (n = 110 and 72), respectively, for ixekizumab. Logistic regression analyses at week 52 are available in Table II .
Significantly more patients in the ixekizumab treatment group than in the ustekinumab treatment group achieved an absolute PASI score of 2 or lower at week 4 and every subsequent time point in a post hoc analysis (Fig 3, F ) . At week 52, 62.7% of the ustekinumab-treated patients (n = 104) had a PASI score of 2 or lower compared with 79.4% of the ixekizumab-treated patients (n = 108). Significantly greater proportions of ixekizumab patients also achieved an absolute PASI score of 5 or lower, 3 or lower, and 1 or lower compared with those in the ustekinumab treatment group ( Supplemental Fig 1; available at http://www.jaad.org).
In a post hoc analysis, calculation of the NNT showed that by week 52, treatment with ixekizumab versus with ustekinumab was associated with 1 additional patient reaching PASI 90 and PASI 100 for every 6 treated (95% CI for PASI 90, 2-5; 95% CI for PASI 100, 3-8); for PASI 75, the NNT at week 52 was 8 patients (95% CI, 4-9).
Efficacy by subgroup. Patients entering IXORA-S who had previously received a biologic (25 in the ustekinumab treatment group and 18 in the ixekizumab treatment group) reported significantly (P = .028) higher PASI 90 response rates at week 52 when treated with ixekizumab than when treated with ustekinumab; significant differences were not seen at an earlier time point or for PASI 100 response rates (Fig 4) . For patients naive to biologic therapies (141 in the ustekinumab treatment group and 118 in the ixekizumab treatment group), treatment with ixekizumab resulted in significantly greater PASI 90 and PASI 100 response rates at both week 12 (P \.001) and week 52 (P \.05) (Fig 4) .
Patients weighing 100.0 kg or less at baseline (121 of those who received ustekinumab and 104 of those who received ixekizumab) reported significantly greater PASI 90 and PASI 100 response rates when treated with ixekizumab than when treated with ustekinumab at both weeks 12 (P \ .05) and 52 (P \ .05) (Fig 4) . With regard to those patients weighing more than 100.0 kg (45 of those who received ustekinumab and 31 of those who received ixekizumab), significantly more of them achieved PASI 90 (P \.05) and PASI 100 (P \.001) at week 12 with ixekizumab treatment than with ustekinumab treatment (Fig 4, A) . At week 52, there was no statistically significant difference in PASI response rates between the ixekizumab-treated patients and the ustekinumab-treated patients (Fig 4, B) .
Regarding baseline severity, patients with a baseline PASI score lower than 20 (107 of those who received ustekinumab and 85 of those who received ixekizumab) were significantly more likely to achieve PASI 90 (P \ .001) or PASI 100 (P \ .01) at week 12 with ixekizumab treatment than with ustekinumab treatment; no significant differences were seen at week 52 (Fig 4, A and B) . Of those patients with a baseline PASI score of 20 or higher (59 of those who received ustekinumab and 51 of those who received ixekizumab), a significantly higher proportion achieved PASI 90 and PASI 100 at week 12 (P \ .01) with ixekizumab treatment than with ustekinumab treatment (Fig 4, A) . The same applied for PASI 90 (P\.001) and PASI 100 (P\.01) (Fig 4, B) at week 52.
Treatment-by-subgroup interactions were observed involving PASI 100 for prior biologic use at week 12, PASI 90 for baseline PASI score and prior biologic use at week 52, and PASI 100 for baseline PASI score at week 52 (Supplemental Table I AEs of special interest. Infections were reported by 107 ustekinumab-treated (64.5%) and 83 ixekizumab-treated (61.5%) patients (Table IV) Injection site reactions were reported by significantly more ixekizumab-treated patients (22 [16.3%] ) than by ustekinumab-treated patients (2 [1.2%]) (P \.001) ( Table IV) . Half of the reactions resolved in 1 day or less. Reactions lasting longer than 1 day were predominately associated with redness and swelling at the injection site.
AEs consisting of allergic reactions and hypersensitivity were no different between treatment groups (in 3 [1.8%] of those who received ustekinumab and in 6 [4.4%] of those who received ixekizumab); no instances of anaphylaxis occurred (Table IV) .
Instances of worsening depressive symptoms were reported by 4 patients; these included 1 case of apathy (in the ixekizumab treatment group) and 3 cases of depressive episodes (in 1 patient who received ustekinumab and in 2 of those who received ixekizumab); rates were not significantly different between treatment groups (Table IV) .
Two cerebrocardiovascular events occurred: 1 myocardial infarction (in the ustekinumab treatment group) and 1 unstable angina (in the ixekizumab treatment group) (Table IV) . No malignancies occurred through week 52. One case of inflammatory bowel disease occurred in the ustekinumab treatment group. The patient reported mild ulcerative colitis beginning at week 31. No concomitant treatment was initiated, and by week 52, the patient was still undergoing treatment and recovering; the study investigator did not deem this event related to the study drug.
There were no instances of grade 4 neutropenia during the 52-week study period. One instance of grade 3 neutropenia occurred (in a patient who received ixekizumab), and 3 cases of grade 2 occurred (in 2 [1.2%] of those who received ustekinumab and 1 [ 0.7%] of those who received ixekizumab) (Supplemental Table II ; available at http:// www.jaad.org). All instances of grade 2 and grade 3 neutropenia were transient and did not result in treatment discontinuation.
DISCUSSION
This 1-year analysis of the IXORA-S study shows that the superiority of ixekizumab over ustekinumab in patients with moderate-to-severe psoriasis was maintained through week 52. A PASI 90 response was sustained through 1 year by 76.5% of the ixekizumab-treated patients, and 52.2% had completely clear skin at week 52 (NRI analysis). When the NNT was considered, the superiority of treatment with ixekizumab over treatment with ustekinumab translated into 1 additional patient reaching PASI 90 for every 3 patients treated at week 12 and for every 6 patients treated by week 52. In terms of absolute PASI, 79.4% of those in the ixekizumab treatment group reported minimal or no disease activity (PASI #2) at week 52 compared with 62.7% of the ustekinumabtreated patients (NRI analysis). Antitumor necrosis factor agents initially provided robust skin improvements; however, the efficacy rates waned over time. [20] [21] [22] Ustekinumab was the first available psoriasis treatment targeting IL-12/23 and has been shown to be efficacious and well-tolerated for the treatment of psoriasis. 12, 13, 23 The types of common AEs and rates of discontinuation in IXORA-S for the ustekinumab and ixekizumab treatment groups were comparable and in line with those reported in previous trials of these treatments 7, 8, 12, 13, 23 and those of other biologic agents. 10, 11, 24, 25 The IXORA-S study is the second clinical trial establishing superiority of an IL-17A inhibitor to the antieIL-12/23 antibody ustekinumab. 9, 11 One major differentiator between this trial and the CLEAR trial, which examined the IL-17A inhibitor secukinumab, is the patient population's experience with a systemic agent. Whereas the CLEAR trial enrolled both systemic experienced (68% of patients) and systemic agentenaive patients, 11 the patients randomized in IXORA-S were required to have previous experience with systemic agents (92% of patients) or a contraindication to them. 16 Of note, in the CLEAR trial, ustekinumab treatment resulted in levels of skin improvements at week 52 that were comparable to those seen here in IXORA-S. Across both trials, secukinumab and ixekizumab treatment resulted in clinically meaningful improvements in skin outcomes, and all 3 treatments had clinically acceptable safety profiles.
Some limitations of this study are that IXORA-S was not designed to compare safety end points related to rare events; thus, any safety comparisons should be considered with caution. However, this trial is the first to provide 52-week comparative data for ixekizumab. Additionally, although 1-year data are informative for patients and physicians, even longer-term efficacy data and real-world registries are needed to fully assess sustained efficacy and safety outcomes. Overall, in the IXORA-S study, ixekizumab provided high efficacy rates, regardless of disease severity at baseline, through 1 year of treatment. Treatment-by-subgroup interactions were tested using logistic regression with nonresponser imputation including terms for treatment, weight, geographic region, subgroup, and subgroupby-treatment interaction. P values are considered significant if less than .2; significant P values are bolded. PASI 90, 90% or greater improvement in Psoriasis Area Severity Index score from baseline; PASI 100, 100% improvement in Psoriasis Area Severity Index score from baseline.
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